US EditionScientists Discover How Leukemia Cells “Cheat Death” and Evade Treatment
- Researchers from Rutgers Health and collaborating institutions uncovered why venetoclax resistance occurs in leukemia, identifying small-molecule OPA1 inhibitors as a possible method to reverse it.
- Scientists determined that OPA1 levels rise in resistant cells, tightening mitochondrial cristae to trap cytochrome c and prevent apoptosis, senior study author Christina Glytsou explained.
- In mice transplanted with human leukemia cells, two experimental OPA1 inhibitors combined with venetoclax at least doubled survival and worked across subtypes including p53-mutant leukemia cells.
- Although early, the team says lead OPA1 compounds from the University of Padua require refinement before human testing, and preclinical tests showed no harm to normal blood cell production.
- About 11,000 Americans die from acute myeloid leukemia annually, and the study points to a promising new strategy targeting OPA1 overexpression in other cancer types.
15 Articles
15 Articles
Scientists Discover How Leukemia Cells “Cheat Death” and Evade Treatment
Scientists have discovered how leukemia cells outsmart a leading treatment and may have found a way to stop them. Scientists from Rutgers Health and collaborating institutions have uncovered why a widely used leukemia drug stops working for many patients and have identified a possible method to reverse that resistance. The research team found that a [...]
Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation - - Second approved...
Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia - Syndax Pharmaceuticals (NASDAQ:SNDX)
– First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation – – Second approved indication for Revuforj in less than one year further solidifies Syndax's leadership in menin inhibition – – Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for R/R NPM1 mutated AML – – Syndax to host conference call today at 2:30 p.m. ET – NEW YORK…
Isabel Veloso, 19 years old, was submitted to a bone marrow transplant and the donor was his father, Joelson Veloso, 50 years old. The influences are in oncological treatment since 2015, when he was diagnosed with Hodgkin lymphoma. The bone marrow transplant is, in fact, a transplant of stem cells. This procedure is essential to treat serious blood and immune system diseases such as leukemia, lymphomas, medula aplasia, immunodeficiency syndrome …
A number of leukemia diseases have proven to be therapy-resistant in recent years, including acute myeloid leukemia (AML), which is mainly associated with increasing age, a disease in which the precursor cells degenerate into white and red blood cells and rapidly multiply. Why leukemia patients suffering from AML do not respond to therapies or poorly respond to...
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
